Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases
Authors:
- Richard W BrownRBRichard W Brown
- Mamoun YounesMYMamoun Younes
- Margaret M GondoMGMargaret M Gondo
- Mark A StephensonMSMark A Stephenson
- Philip T CaglePCPhilip T Cagle
- 1 September 1997
- journal article
- Published by Elsevier in Human Pathology
- Vol. 28 (9) , 1079-1082
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Expression of bcl-2 protein in stage T1NOMO non-small cell lung carcinomaHuman Pathology, 1995
- Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancerBritish Journal of Cancer, 1995
- What is the value of bcl‐2 protein detection for histopathologists?Histopathology, 1995
- Loss of Heterozygosity at the bcl‐2 Gene Locus and Expression of bcl‐2 in Human Gastric and Colorectal CarcinomasJapanese Journal of Cancer Research, 1994
- The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor statusVirchows Archiv, 1994
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinomaInternational Journal of Cancer, 1993
- Immunolocalization of the Bcl-2 protein within hematopoietic neoplasmsBlood, 1991
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990